
|Articles|February 1, 2004
Less AD in adult populations
Anaheim Hills, Calif. - The new topical immunomodulators (TIMs) such as pimecrolimus (Elidel) and tacrolimus (Protopic) will reverse the growing number of cases of adult atopic dermatitis, predicts Cheryl Effron, M.D., a dermatologist in Anaheim Hills, Calif.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Phase 2 Nemolizumab Trial Opens for CPUO
5


















